Point of Care Receives FDA CLEARANCE FOR BREAKTHROUGH DRUG DETECTION PRODUCT

    Herndon, Va.(Business Wire)Nov. 13, 1997The rapidly growing field
of onsite drug abuse screening took a significant step forward with the
FDA granting 510(k) clearance for the Fingerprint Drug Screening Device(TM).

    The innovative device provides the first permanent record and
eliminates chain of custody issues by effectively linking sample results to
an identifiable fingerprint of the donor.

    Developed and marketed by Point of Care Technologies Inc. (Point of
Care), the rapid noninstrument assay was created to detect the presence of
illicit drugs in urine while combating the dispute surrounding drug test
identification.

    "Our product solves deficiencies in the current drug screening
process," stated Michael R. Pratt, Point of Care president and CEO. "It is
the only answer to the chain of custody dilemma that has been haunting both
law enforcement officials and the judicial Point of Care president and CEO.
"It is the only answer to the chain of custody dilemma that has been
haunting both law enforcement officials an

    Point of Care developed the Fingerprint Drug Screening Device in
response to market demand for a solution to the chain of custody problems,
mishandling of results and other related issues.

    With increased health care costs and the growing concern over the use
of illicit drugs, testing for drug abuse is now necessary in more and more
environments. The Fingerprint Drug Screening Device tests for amphetamines,
cocaine, opiates, PCP and THC (marijuana) in minutes, meets all NIDA
(National Institute on Drug Abuse) cutoff standards and can be easily
administered.

    "This 510(k) clearance of our Fingerprint Drug Screening Device allows
Point of Care to complete its first product entry into the drug screening
market. We expect the clearance of our second product, the 'Genie Cup'
within the first quarter of 1998," stated Brian Harmison, vice president of
sales and marketing.

    Point of Care, based in Herndon, Va., is an emerging leader in the
development and distribution of efficient and reliable screening and
diagnostic products for use in the home and at the point of care. Point of
Care is traded on the NASDAQ bulletin board under the symbol PCIT.

CONTACT: Point of Care Technologies Inc.

Brian Harmison, 703/7130589 or Arnold Public Relations Robert Ranson,
703/9057173